Ambitious AB Science Gets Masitinib Win For Severe Asthma
Drug In Trials For Seven Indications
Plagued by concerns on the integrity of data and compliance issues with its clinical practices, the French firm still believes masitinib could be effective for ALS, multiple sclerosis, cancers, asthma and even Alzheimer's.
You may also be interested in...
AB Science’s top-line results from a Phase III study suggest its lead candidate masitinib may be of benefit when combined with docetaxel chemotherapy in patients with early metastatic castration-resistant prostate cancer.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
A retrospective analysis of new drugs evaluated by the European Medicines Agency since 2010 shows that a lack of, or major deficiencies in, human mass balance studies is still a concern in regulatory submissions.